Skip to main content

Table 7 Effect on the model of gastric cancer by L-OHP, CIK, L-OHP+CIK ( x ¯ ± S).

From: Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro

Group n Abdominal perimeter (cm) Existed time (d) Survival rate (35d)
Normal control group 5 8.8 ± 0.4 60 ± 0 5/5
NS control group 5 15.61 ± 0.5 20 ± 3.5 0/5
L-OHP1.125 mg/kg 5 14.45 ± 0.3a 38 ± 4.2a 3/5a
L-OHP2.25 mg/kg 5 12.15 ± 0.2a 52 ± 3.8a 4/5a
CIK2 × 107/0.2 mL 5 13.90 ± 0.2a 40 ± 4.6a 3/5a
CIK4 × 107/0.2 mL 5 11.87 ± 0.2a 53 ± 4.3a 4/5a
L-OHP+CIK 5 8.46 ± 0.3ab 60 ± 0ab 5/5ab
  1. a) P < 0.01 Compared with NS control group
  2. b) P > 0.01 Compared with normal control group